News articles about Zoetis (NYSE:ZTS) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Zoetis earned a news impact score of 0.22 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.8547658706093 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Zoetis Inc. (ZTS) stock is now worth at $85.30 while Analyst mean rating stands at 1.90 (nasdaqfortune.com)
- Zoetis launches #MyVetIsCore sweepstakes (veterinarypracticenews.com)
- Zoetis (ZTS) Given a $90.00 Price Target by Cantor Fitzgerald Analysts (americanbankingnews.com)
- Global Swine Vaccines Market 2018- CAHIC, Tecon, Zoetis, Ceva, Hile Bio, Chopper Biology, WINSUN, Hipra, Ringpu … (healthcaretrends24.com)
- Zoetis Inc. (ZTS) Significant Movements (thestocksnews.com)
Shares of Zoetis stock traded down $0.95 on Tuesday, reaching $84.35. The stock had a trading volume of 1,909,427 shares, compared to its average volume of 2,710,550. Zoetis has a 1 year low of $54.70 and a 1 year high of $86.38. The company has a market cap of $41,464.93, a price-to-earnings ratio of 35.15, a PEG ratio of 1.89 and a beta of 0.96. The company has a current ratio of 3.85, a quick ratio of 2.55 and a debt-to-equity ratio of 2.77.
Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 15th. The company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.03. Zoetis had a net margin of 16.28% and a return on equity of 65.96%. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the prior year, the firm posted $0.47 earnings per share. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. sell-side analysts predict that Zoetis will post 3.04 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, April 20th will be issued a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date is Thursday, April 19th. Zoetis’s payout ratio is 20.83%.
Several equities analysts recently weighed in on the stock. Cantor Fitzgerald set a $90.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Tuesday. BMO Capital Markets set a $78.00 price target on shares of Zoetis and gave the company a “hold” rating in a research report on Thursday, February 15th. Piper Jaffray set a $88.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research report on Friday, February 16th. Jefferies Group reiterated a “buy” rating and set a $96.00 target price on shares of Zoetis in a research report on Friday, April 13th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $86.00 target price (up previously from $84.00) on shares of Zoetis in a research report on Friday, February 16th. One analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. Zoetis presently has an average rating of “Buy” and a consensus price target of $81.61.
In related news, insider Heidi C. Chen sold 37,453 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $81.02, for a total value of $3,034,442.06. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Roxanne Lagano sold 35,663 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $81.02, for a total transaction of $2,889,416.26. Following the completion of the sale, the executive vice president now directly owns 49,919 shares in the company, valued at $4,044,437.38. The disclosure for this sale can be found here. Over the last three months, insiders sold 112,952 shares of company stock worth $9,219,843. Insiders own 0.35% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2018/04/24/zoetis-zts-receiving-somewhat-positive-news-coverage-analysis-shows.html.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.